GSK strikes US$10.6B Nuvalent deal to strengthen lung cancer pipeline

UK—GSK has agreed to acquire U.S. biotechnology firm Nuvalent in a US$10.6 billion all-cash transaction to accelerate its presence in precision oncology, particularly in lung cancer treatments.

The deal gives GSK access to two late-stage drug candidates that the company believes could generate multi-blockbuster sales if approved.

The acquisition comes as GSK intensifies its shift toward oncology to offset expected revenue pressure from upcoming patent expirations in its HIV franchise.

Under the agreement, GSK will pay US$124 per share, a 40% premium over Nuvalent’s last closing price of US$88.49.

The company plans to finance the transaction through a combination of existing cash reserves and new debt facilities, while maintaining its full-year financial guidance.

Market observers note that the scale of the deal places it among GSK’s largest acquisitions, second only to its 2015 asset swap with Novartis, valued at about US$20 billion.

Late-stage lung cancer assets drive strategy

The acquisition centers on zidesamtinib and neladalkib, two investigational therapies targeting ROS1 and ALK alterations in non-small cell lung cancer (NSCLC).

Both assets have received breakthrough therapy and orphan drug designations from the U.S. Food and Drug Administration, reflecting strong early clinical performance in heavily pretreated patients.

GSK expects regulatory decisions on zidesamtinib by mid-September, followed by a ruling on neladalkib the following month.

If approved, the company plans to begin launches in 2026, positioning both drugs as potential best-in-class treatments.

NSCLC accounts for roughly 85% of lung cancer cases, a disease area that remains one of the leading global causes of cancer mortality, according to the World Health Organization.

Strategic shift under new leadership

The deal marks a notable move under GSK’s new chief executive Luke Miels, who took over leadership earlier this year following Emma Walmsley’s tenure.

Miels has previously focused on smaller bolt-on acquisitions and licensing agreements, but the Nuvalent acquisition signals a broader push into late-stage, high-value oncology assets.

The company continues to face investor scrutiny over its long-term revenue mix, particularly as its HIV drug Tivicay (dolutegravir) approaches patent expiry in 2028.

That medicine, part of the combination therapy Dovato, generated US$3.6 billion in 2025 sales, highlighting its importance to the company’s core business.

Oncology growth and industry competition

GSK’s oncology division has emerged as a key growth driver, expanding by 43% in 2025 to reach approximately US$2.7 billion.

The company is now seeking to narrow the gap with competitors such as AstraZeneca, which has built a dominant oncology portfolio that accounts for a large share of its revenue.

Recent market commentary has highlighted increasing competition in targeted cancer therapies, as pharmaceutical firms race to secure next-generation precision medicines and strengthen late-stage pipelines.

Analysts also point to heightened deal activity across the sector as companies position themselves ahead of major patent cliffs and shifting treatment standards in lung cancer and other solid tumors.